A randomized phase II study on the effects of 5-Aza-2′-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: An EORTC Leukemia Cooperative Group phase II study (06893)

Leukemia

Volumn 11, Issue SUPPL. 1, 1997, Pages

  Willemze, R ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

5 Aza 2 deoxycytidine; Acute leukemia; Relapse

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AMSACRINE; ANTILEUKEMIC AGENT; IDARUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DIARRHEA; GASTROINTESTINAL TOXICITY; HEART ARRHYTHMIA; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

EID: 0030965033     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (2)

1. Willemze R, Archimbaud E, Muus P for the EORTC Leukemia Cooperative Group. Preliminary results with 5-Aza-2′-deoxycytidine (DAC)-containing chemotherapy in patients with relapsed or refractory acute leukemia. Leukemia 1993; 7: 49-50.
2. Momparler R et al. Leukemia 1993; 7 (Suppl 1): 17-20.